Alnylam Pharmaceuticals Inc (NASDAQ:ALNY)

104.20
Delayed Data
As of Jun 22
 +1.51 / +1.47%
Today’s Change
70.76
Today|||52-Week Range
153.99
-17.99%
Year-to-Date

Today’s Trading

Previous close102.69
Today’s open103.02
Day’s range101.68 - 104.31
Volume711,365
Average volume (3 months)934,812
Market cap$10.4B
Data as of 4:00pm ET, 06/22/2018

Growth & Valuation

Earnings growth (last year)-13.15%
Earnings growth (this year)-30.41%
Earnings growth (next 5 years)+163.00%
Revenue growth (last year)+90.66%
P/E ratioNM
Price/Sales127.96
Price/Book5.82

Competitors

 Today’s
change
Today’s
% change
ALKSAlkermes Plc+0.48+1.10%
SGENSeattle Genetics Inc+0.24+0.36%
TSROTESARO Inc+3.87+8.46%
JAZZJazz Pharmaceuticals...-1.63-0.90%
Data as of 4:00pm ET, 06/22/2018

Financials

Next reporting dateAugust 9, 2018
EPS forecast (this quarter)-$1.78
Annual revenue (last year)$89.9M
Annual profit (last year)-$490.9M
Net profit margin-545.95%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
John M. Maraganore
President
Barry E. Greene
Corporate headquarters
Cambridge, Massachusetts

Forecasts